Compare DLNG & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLNG | FATE |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.8M | 125.6M |
| IPO Year | 2013 | 2013 |
| Metric | DLNG | FATE |
|---|---|---|
| Price | $3.89 | $2.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 52.4K | ★ 1.8M |
| Earning Date | 05-26-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.10 | N/A |
| P/E Ratio | $3.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.27 | $0.93 |
| 52 Week High | $4.45 | $3.23 |
| Indicator | DLNG | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 53.02 | 39.37 |
| Support Level | $3.78 | $2.25 |
| Resistance Level | $3.91 | $2.88 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 59.20 | 0.17 |
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and is winterized, which enables trade in subzero and ice bound conditions.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.